182 related articles for article (PubMed ID: 29288236)
1. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.
Michaels AD; Newhook TE; Adair SJ; Morioka S; Goudreau BJ; Nagdas S; Mullen MG; Persily JB; Bullock TNJ; Slingluff CL; Ravichandran KS; Parsons JT; Bauer TW
Clin Cancer Res; 2018 Mar; 24(6):1415-1425. PubMed ID: 29288236
[No Abstract] [Full Text] [Related]
2. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
[TBL] [Abstract][Full Text] [Related]
3. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.
Zhu H; Leiss L; Yang N; Rygh CB; Mitra SS; Cheshier SH; Weissman IL; Huang B; Miletic H; Bjerkvig R; Enger PØ; Li X; Wang J
Oncotarget; 2017 Feb; 8(7):12145-12157. PubMed ID: 28076333
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
[No Abstract] [Full Text] [Related]
5. CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis.
Morrissey MA; Kern N; Vale RD
Immunity; 2020 Aug; 53(2):290-302.e6. PubMed ID: 32768386
[TBL] [Abstract][Full Text] [Related]
6. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
Seckinger A; Buatois V; Moine V; Daubeuf B; Richard F; Chatel L; Viandier A; Bosson N; Rousset E; Masternak K; Salgado-Pires S; Batista C; Mougin C; Juan-Bégeot F; Poitevin Y; Hose D
Front Immunol; 2024; 15():1378813. PubMed ID: 38720892
[TBL] [Abstract][Full Text] [Related]
7. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
8. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
[No Abstract] [Full Text] [Related]
9. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
[TBL] [Abstract][Full Text] [Related]
10. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Theruvath J; Menard M; Smith BAH; Linde MH; Coles GL; Dalton GN; Wu W; Kiru L; Delaidelli A; Sotillo E; Silberstein JL; Geraghty AC; Banuelos A; Radosevich MT; Dhingra S; Heitzeneder S; Tousley A; Lattin J; Xu P; Huang J; Nasholm N; He A; Kuo TC; Sangalang ERB; Pons J; Barkal A; Brewer RE; Marjon KD; Vilches-Moure JG; Marshall PL; Fernandes R; Monje M; Cochran JR; Sorensen PH; Daldrup-Link HE; Weissman IL; Sage J; Majeti R; Bertozzi CR; Weiss WA; Mackall CL; Majzner RG
Nat Med; 2022 Feb; 28(2):333-344. PubMed ID: 35027753
[TBL] [Abstract][Full Text] [Related]
11. Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma.
Liu X; Zhang H; Wang C; Li Z; Zhu Q; Feng Y; Fan J; Qi S; Wu Z; Liu Y
Curr Neuropharmacol; 2023; 21(10):2159-2173. PubMed ID: 37171006
[TBL] [Abstract][Full Text] [Related]
12. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models.
Thomas RM; Gharaibeh RZ; Gauthier J; Beveridge M; Pope JL; Guijarro MV; Yu Q; He Z; Ohland C; Newsome R; Trevino J; Hughes SJ; Reinhard M; Winglee K; Fodor AA; Zajac-Kaye M; Jobin C
Carcinogenesis; 2018 Jul; 39(8):1068-1078. PubMed ID: 29846515
[TBL] [Abstract][Full Text] [Related]
13. CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis.
Shi H; Wang X; Li F; Gerlach BD; Yurdagul A; Moore MP; Zeldin S; Zhang H; Cai B; Zheng Z; Valenti L; Tabas I
Sci Transl Med; 2022 Nov; 14(672):eabp8309. PubMed ID: 36417485
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect.
Nishiga Y; Drainas AP; Baron M; Bhattacharya D; Barkal AA; Ahrari Y; Mancusi R; Ross JB; Takahashi N; Thomas A; Diehn M; Weissman IL; Graves EE; Sage J
Nat Cancer; 2022 Nov; 3(11):1351-1366. PubMed ID: 36411318
[TBL] [Abstract][Full Text] [Related]
15. Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles.
Rao L; Zhao SK; Wen C; Tian R; Lin L; Cai B; Sun Y; Kang F; Yang Z; He L; Mu J; Meng QF; Yao G; Xie N; Chen X
Adv Mater; 2020 Nov; 32(47):e2004853. PubMed ID: 33089578
[TBL] [Abstract][Full Text] [Related]
16. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.
Busato D; Capolla S; Durigutto P; Mossenta M; Bozzer S; Sblattero D; Macor P; Dal Bo M; Toffoli G
J Transl Med; 2023 Nov; 21(1):864. PubMed ID: 38017492
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.
Candas-Green D; Xie B; Huang J; Fan M; Wang A; Menaa C; Zhang Y; Zhang L; Jing D; Azghadi S; Zhou W; Liu L; Jiang N; Li T; Gao T; Sweeney C; Shen R; Lin TY; Pan CX; Ozpiskin OM; Woloschak G; Grdina DJ; Vaughan AT; Wang JM; Xia S; Monjazeb AM; Murphy WJ; Sun LQ; Chen HW; Lam KS; Weichselbaum RR; Li JJ
Nat Commun; 2020 Sep; 11(1):4591. PubMed ID: 32929084
[TBL] [Abstract][Full Text] [Related]
18. Inducing Tumor Suppressive Microenvironments through Genome Edited CD47
Jayaraman Rukmini S; Bi H; Sen P; Everhart B; Jin S; Ye K
Sci Rep; 2019 Dec; 9(1):20057. PubMed ID: 31882679
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments.
Benesova I; Capkova L; Ozaniak A; Pacas P; Kopeckova K; Galova D; Lischke R; Buchler T; Ozaniak Strizova Z
J Cancer Res Clin Oncol; 2024 Mar; 150(3):134. PubMed ID: 38493445
[TBL] [Abstract][Full Text] [Related]
20. Human CD47-Derived Cyclic Peptides Enhance Engulfment of mAb-Targeted Melanoma by Primary Macrophages.
Jalil AR; Andrechak JC; Hayes BH; Chenoweth DM; Discher DE
Bioconjug Chem; 2022 Nov; 33(11):1973-1982. PubMed ID: 35285229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]